The Intracerebral Hemorrhage drugs in development market research report provides comprehensive information on the therapeutics under development for Intracerebral Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Intracerebral Hemorrhage. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Intracerebral Hemorrhage and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Intracerebral Hemorrhage by 14 companies/universities/institutes. The top development phase for Intracerebral Hemorrhage is phase ii with eight drugs in that stage. The Intracerebral Hemorrhage pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Intracerebral Hemorrhage pipeline products market are: Swedish Orphan Biovitrum, Hokkaido University and Simcere Pharmaceutical Group.
The key targets in the Intracerebral Hemorrhage pipeline products market include Free Radical, Interleukin 1 Receptor Type 1, and Interleukin 1.
The key mechanisms of action in the Intracerebral Hemorrhage pipeline product include Free Radical Scavenger with two drugs in Phase II. The Intracerebral Hemorrhage pipeline products include ten routes of administration with the top ROA being Intravenous and ten key molecule types in the Intracerebral Hemorrhage pipeline products market including Small Molecule, and Synthetic Peptide.
Intracerebral Hemorrhage overview
Intracerebral hemorrhage (ICH), a devastating stroke subtype, involves the formation of a hematoma within the brain parenchyma, with or without extension into the ventricles. Accounting for 10-15% of all strokes, non-traumatic ICH is linked to high morbidity and mortality. Risk factors encompass chronic hypertension, amyloid angiopathy, anticoagulation, and vascular malformations. The resulting brain injury is categorized as primary, signifying initial damage by the blood clot, or secondary, indicating complications from intracranial blood. Management options for ICH span from medical therapy to surgical evacuation of the hematoma, prompting ongoing studies for less invasive interventions to enhance prognosis.
For a complete picture of Intracerebral Hemorrhage’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
